Virology News
188.5K views | +0 today
Follow
Virology News
Topical news snippets about viruses that affect people.  And other things. Like Led Zeppelin. And zombies B-)
Curated by Ed Rybicki
Your new post is loading...
Your new post is loading...
Scooped by Ed Rybicki
Scoop.it!

Billions of dollars later and still no Aids vaccine - Times LIVE

Billions of dollars later and still no Aids vaccine - Times LIVE | Virology News | Scoop.it
Latest news from South Africa, World, Politics, Entertainment and Lifestyle. The home of The Times and Sunday Times newspaper. (The hunt for an HIV vaccine has gobbled up $8-billion in the past decade with no real results.
Ed Rybicki's insight:

Beause of rampant band-wagon jumping and some ignoring of basic lessons from other lentiviruses...the Ad5 bandwagon was especially noticeable; it will be interesting to see what the new wagon will be, now that this has come to a grinding halt.  Poxviruses, anyone?

No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Ineffective – HIV Vaccine Trial Discontinued

Ineffective – HIV Vaccine Trial Discontinued | Virology News | Scoop.it

The National Institute of Allergy and Infectious Diseases (NIAID) has announced that it will halt its HVTN 505 HIV vaccine

trial due to a perceived lack of efficacy. A scheduled review by an independent data and safety monitoring board found that the vaccine regimen neither prevented HIV infection nor reduced viral load in vaccine recipients who became infected with HIV.

The announcement will come as a blow to those hoping the HVTN 505 would be an effective intervention to stem the HIV pandemic.

 

HIV particle graphic by Russell Kightley Media

Ed Rybicki's insight:

And another one bites the dust...not only not effective, but suspected of increasing infection rates.  VERY sad!

 

I am beginning to think that adenoviruses are simply useless when it comes to vectoring HIV genes for vaccine purposes.

No comment yet.
Scooped by Ed Rybicki
Scoop.it!

Is this the reason why RV144 HIV ‘Thai trial’ didn’t protect more participants?

Is this the reason why RV144 HIV ‘Thai trial’ didn’t protect more participants? | Virology News | Scoop.it

The RV144 ‘Thai trial’ of an HIV vaccine candidate resulted in an unprecedented 31% protection rate among participants – a

result that sparked something of a revival in the HIV vaccine field. Despite this encouraging result, the protection rate was still considered to be too low for the vaccine to be useful. Since then, many HIV vaccines have come and gone – with the NIAID’s HVTN 505 trial being the latest casualty in the drive to stem the HIV pandemic. However, researchers at the Duke Human Vaccine Institute have published researched inProceedings of the National Academy of Sciences (May 6th 2013) which pinpoints a previously unknown interaction between IgA and IgG antibodies as the cause of a lack of response to the RV144 vaccine.

 

Killer T-cell graphic by Russell Kightely Media

Ed Rybicki's insight:

VERY interesting, if true: IgA - supposedly the Ab of choice for mucosal surface protection - interfering with IgG, and stopping killer T / NK cells from binding and killing infected cells?

No comment yet.